KB-1107
ladiratuzumab
Background of ladiratuzumab
LIV-1 is an estrogen-inducible gene that has been implicated in epidermal-to-mesenchymal transition (EMT) in preclinical models of progression and metastasis. Its expression is associated with node-positivity in breast cancer; and has been detected in a variety of cancer types, including estrogen receptor positive breast cancers. ladiratuzumab vedotin (LV), is a novel investigational humanized IgG1 antibody directed against LIV-1.
Specifications
| Catalog Number | KB-1107 |
|---|---|
| Antibody Name | ladiratuzumab |
| Isotype | Human IgG1,kappa |
| Target | LIV-1 |
| Species Reactivity | Human |
| Host Cell Line | EXPI CHO |
| Purification Method | Affinity purified |
| Concentration | >2 mg/mL |
| Formulation | 50 mM sodium citrate,150mM NaCl,pH5.5 |
| Purity | >95% by SDS-PAGE and SEC-HPLC |
| Validation | ELISA|FACS|KD |
| Endotoxin Level | <0.2 EU/mg as determined by the LAL method |
| Sterility | 0.2μm filtered |
| Storage | It is recommended that the protein should be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles. |
| Stability | Stable for twelve months from date of receipt when stored at -20°C to -80°C; Stored at 2-8°C for one month without detectable loss of activity. |
Characterization
Application
References
- Zahedi P, Yoganathan R, Piquette-Miller M and Allen C: Recent advances in drug delivery strategies for treatment of ovarian cancer. Expert Opin Drug Deliv. 9:567–583. 2012.
- Marchion D and Munster P: Development of histone deacetylase inhibitors for cancer treatment. Expert Rev Anticancer Ther. 7:583–598. 2007.